Status Change

CSPC's SYH2070 opens enrollment in a crowded ANGPTL3 lipid-lowering field

The Phase 2 trial moved to active recruitment as at least eight other ANGPTL3-targeted programs, from Arrowhead to Regeneron, run in parallel across related lipid disorders.

CSPC Zhongnuo Pharmaceutical's Phase 2 trial of SYH2070, an ANGPTL3-targeted RNA therapy, moved from Not yet recruiting to Recruiting on July 22, 2026, with a primary completion date of April 30, 2027.

By AppliedXLJuly 22, 2026Trial NCT07695597

Executive Summary

A Phase 2 trial of CSPC Zhongnuo Pharmaceutical's ANGPTL3-targeted therapy moved into active patient recruitment, on schedule with the sponsor's own stated timeline.
The trial enters a mechanism class already populated by multiple industry sponsors running comparable programs in related lipid disorders, from late-stage RNA therapies to an approved monoclonal antibody used outside this specific indication.
With no efficacy or safety data yet posted, the read here is competitive positioning and operational execution rather than a clinical result, and the trial's completion timeline will determine how it stacks up against peers reading out around the same window.
The primary endpoint tests triglyceride reduction at six months, a standard measure in this mechanism class, and the trial's protocol has stayed stable since it first posted.

The status change

The trial, registered as NCT07695597, is testing SYH2070 Injection in participants with mixed hyperlipidemia, a condition marked by elevated triglycerides and LDL cholesterol together. The registry recorded the status shift to Recruiting on July 22, 2026, alongside an update to the actual start date of July 15, 2026, both landing close to the trial's original first-posted timeline of July 10, 2026. The trial targets 240 participants across six arms in China, with a primary completion date set for April 30, 2027, and full completion by September 10, 2027. NCT07695597+1

What the trial tests

The primary endpoint measures the percentage change in serum triglyceride levels from baseline at week 24, a standard lipid-lowering measure for this drug class. Eligible participants must have fasting triglycerides between 150 and 499 mg/dL and LDL-C at or above 100 mg/dL while on stable statin therapy, and the trial excludes anyone who has used another ANGPTL3 inhibitor within six months or a PCSK9 monoclonal antibody within three months before screening. The design is randomized and quadruple-masked across six arms, a structure suited to dose-ranging within a single study. NCT07695597

The competitive field

SYH2070 is not the only ANGPTL3-targeted program active in lipid disorders. Arrowhead Pharmaceuticals' zodasiran, Eli Lilly's solbinsiran, Regeneron's evinacumab, and Regeneron's ALN-ANG3 in diabetic kidney disease all share the ANGPTL3 target across a mix of Phase 1 to Phase 3 programs, and CRISPR Therapeutics' CTX310 and Verve Therapeutics' VERVE-201 extend the same target into gene-editing and gene-therapy modalities. Regeneron's evinacumab is approved for homozygous familial hypercholesterolemia, a different indication from mixed hyperlipidemia, so it stands as a validated mechanism precedent rather than an approved option in this specific trial's population.

Where SYH2070 sits

Within mixed hyperlipidemia and ANGPTL3 specifically, SYH2070 is the only trial recorded at this target-indication intersection, and it is also the only Phase 2 asset in that narrow pairing, with nine sibling trials targeting related lipid receptors in the same disease. The broader ANGPTL3 field has slowed, with 259 recent trials against 1,110 older ones, a decline ratio that points to a mechanism class past its early growth phase but still advancing through Arrowhead's and Regeneron's later-stage programs. That structural mix, a mechanism already validated by an approved drug in a related indication and multiple sponsors in Phase 2 or Phase 3, means SYH2070's readout will be measured against a triglyceride-reduction bar the field has already begun to establish, not against an unproven target.

Sponsor track record

CSPC Zhongnuo has completed all six of its prior trials with none terminated, and its broader pipeline runs 28 trials across a mix of recruiting, not-yet-recruiting, and completed statuses. The trial's protocol has recorded no amendments beyond the status update since it first posted, a pattern the registry-churn proxy labels stable. NCT07695597

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.